TUSTIN, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company developing targeted therapeutics for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that senior management will present at the BIO CEO & Investor Conference 2007 on Wednesday, February 14, 2007 at 12:00 pm EST. The conference will be held at the Waldorf Astoria Hotel in New York City.
Peregrine CEO and president Steven W. King will provide a review of recent corporate developments.
Mr. King's presentation will be webcast live and can be accessed by visiting the Investor Relations section of Peregrine's website at www.peregrineinc.com. A replay will be available on the Peregrine website and archived for approximately 30 days.
For more information about this conference, please visit: http://ceo.bio.org/opencms/ceo/2007/index.jsp About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing five separate clinical trials in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R) in the U.S. and India. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Contacts: GendeLLindheim BioCom Partners Investors Media info@peregrineinc.com Barbara Lindheim (800) 987-8256 (212) 918-4650
Peregrine Pharmaceuticals, Inc.CONTACT: Investors, +1-800-987-8256, info@peregrineinc.com, or Media,Barbara Lindheim, +1-212-918-4650, both of GendeLLindheim BioCom Partners,for Peregrine Pharmaceuticals, Inc.
